Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9186.026 | 1.0802 | 1.3261 | 0.5108 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9186.026 | 1.1465 | 1.6137 | 0.5108 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9186.026 | 1.0900 | 1.3676 | 0.5108 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9186.026 | 1.0634 | 1.2560 | 0.5108 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9186.026 | 1.0453 | 1.1811 | 0.5108 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9186.026 | 1.0449 | 1.1796 | 0.5108 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 9186.026 | 1.0910 | 1.3717 | 0.5108 | |
| BT-483 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 9186.026 | 1.0461 | 1.1843 | 0.5108 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7803.042 | 1.0067 | 1.0048 | 2.8270 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7803.042 | 1.0303 | 1.0212 | 2.8270 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7803.042 | 1.0538 | 1.0374 | 2.8270 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7803.042 | 1.1083 | 1.0741 | 2.8270 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7803.042 | 1.0632 | 1.0438 | 2.8270 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7803.042 | 1.0001 | 1.0001 | 2.8270 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7803.042 | 0.9522 | 0.9656 | 2.8270 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7803.042 | 0.9681 | 0.9772 | 2.8270 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7803.042 | 0.7339 | 0.7927 | 2.8270 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7804.042 | 1.0020 | 1.0016 | 2.4955 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7804.042 | 1.0009 | 1.0007 | 2.4955 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7804.042 | 1.0135 | 1.0108 | 2.4955 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7804.042 | 1.0212 | 1.0169 | 2.4955 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7804.042 | 1.0241 | 1.0192 | 2.4955 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7804.042 | 1.0113 | 1.0090 | 2.4955 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7804.042 | 1.0222 | 1.0176 | 2.4955 | |
| BT-549 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7804.042 | 1.0092 | 1.0074 | 2.4955 |